Survey of Drug Oxidation Activities in Hepatic and Intestinal Microsomes of Individual Common Marmosets, A New Nonhuman Primate Animal Model

Shotaro Uchara¹, Toru Oshio¹, Kazuyuki Nakanishi¹, Etsuko Tomioka¹, Miyu Suzuki¹, Takashi Inoue², Yasuhiro Uno³, Erika Sasaki⁴, and Hiroshi Yamazaki⁵,†

¹Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan; ²Department of Marmoset Research, Central Institute for Experimental Animals, Kawasaki, Japan; ³Shin Nippon Biomedical Laboratories, Ltd., Kainan, Wakayama, Japan; and ⁴Keio Advanced Research Center, Keio University, Minato-ku, Tokyo, Japan

Abstract: Background: Common marmosets (Callithrix jacchus) are potentially useful nonhuman primate models for preclinical studies. Information for major drug-metabolizing cytochrome P450 (P450) enzymes is now available that supports the use of this primate species as an animal model for drug development. Here, we collect and provide an overview of information on the activities of common marmoset hepatic and intestinal microsomes with respect to 28 typical human P450 probe oxidations.

Keywords: Marmoset, CYP3A4, CYP2D6, CYP2C19, Polymorphism, PBPK.

1. INTRODUCTION

The human cytochrome P450 gene superfamily comprises 57 functional genes and 58 pseudogenes [1]. The corresponding cytochrome P450 [P450 (EC 1.14.14.1)] enzymes are involved in the oxidative metabolism of a variety of endogenous and exogenous compounds and clinical medicines. In drug development, rodents are often used as preclinical animal models. However, it is well known that species differences exist in terms of drug oxidation activities mediated mainly by rodent and human P450 isoforms [2]. Common marmosets (Callithrix jacchus), New World monkeys, are attractive as small non-human primate models in drug metabolism studies due to genetic closeness, small body size, early sexual maturity, and high reproductive efficacy [3]. It has been reported that the metabolic profile of di(2-ethylhexyl)phthalate in marmosets was similar to that in humans, but not to that in rats [4]. Recently, an increasing amount of information on the characterization of cytochrome P450 enzymes has become available for marmosets, including information on P450 1A/B, 2A/B/C/D/E/F/I, 3A, and 4A/F [5, 6]. Toxicological research revealed that marmoset P450 2D6 activated and deactivated the potential pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [6]. It should be noted that all the P450s described in this study were named by the P450 Nomenclature Committee (http://dmlson.uthsc.edu/cytochromeP450.html) [7, 8]. Sequence similarity of P450 cDNA and amino acids between marmosets and humans are summarized in Table 1.

In common marmosets, significantly faster in vivo clearance of S-warfarin than R-warfarin was observed after administration of racemic warfarin [9, 10], a finding consistent with warfarin stereoselectivity in humans [11]. In humans, warfarin is mainly metabolized by P450 2C9. However, marmosets do not possess the P450 2C9 gene: instead, marmoset P450 2C19 mainly mediates the oxidations of human P450 2C9 and 2C19 substrates such as warfarin and omeprazole [12]. The in vivo pharmacokinetics of racemic warfarin and omeprazole have been shown to be related to marmoset P450 2C19 [F7L; S254L; I469T] [13]. The utility of physiologically based pharmacokinetic models was demonstrated in marmosets to help elucidate the inter-individual differences in the pharmacokinetics of R-omeprazole and S-warfarin associated with polymorphic P450 2C19 [14]. Moreover, the effects of aging or induction on some drug clearances mediated by marmoset P450 enzymes were evident in experiments on older animals and animals pretreated with rifampicin [15]. Additionally, marmoset P450 3A enzymes were strongly induced by exogenous rifampicin in vitro [16] and in vivo [15], just as human P450 3A enzymes are. Age-related pharmacokinetic changes in animal models could reveal important information during drug development for elderly patients.

Over the past few years, in separate studies, we have accumulated data on drug oxidation activities in hepatic microsomes and intestinal microsomes from marmosets [12-14, 17-33]. These data, along with the catalytic activities of recombinant P450 enzymes co-expressed with NADPH-cytochrome P450 reductase in bacterial membranes, are summarized in the current article. Moreover, we describe species and individual differences in marmoset P450 enzyme activities in hepatic and intestinal microsomes involved in...
drug oxidations associated with pharmacological and/or toxicological effects.

2. DRUG OXIDATION ACTIVITIES MEDIATED BY MARMOSET HEPATIC MICROSOMES

The oxidation activities of commercially available pooled hepatic microsomes from humans, monkeys, and marmosets and from individual marmosets obtained from the Central Institution for Experimental Animals (Kawasaki, Japan) for 26 substrates oxidized to 28 metabolites are plotted in Fig. (1). The numbers of available liver samples from individual marmosets ranged from 14 to 36 in these reactions. Marmoset hepatic microsomes catalyzed 7-ethoxyresorufin O-deethylation and 7-ethoxycoumarin O-deethylation (typical human P450 1A and 1B probe reactions) with similar activities to those of humans and cynomolgus monkeys [22, 33]. The catalytic activities of recombinant marmoset P450 1A1 and 1A2 for these reactions were comparable to those of humans and cynomolgus monkeys [22, 33]. Marmoset hepatic microsomes did not show substantial coumarin 7-hydroxylation activities, unlike human and cynomolgus monkey hepatic microsomes [17]. This fact can be explained by the considerably low activity of this reaction mediated by recombinant marmoset P450 2A6 (Table 2). Pooled hepatic microsomes from humans, cynomolgus monkeys, and marmosets catalyzed pentoxyresorufin O-depentylation, propofol 4-hydroxylation, and efavirenz 8-hydroxylation (typical human P450 2B6 substrates) [30]. However, the role of P450 enzymes in efavirenz 8-hydroxylation in marmoset and human livers may be different because of the low enzyme activity of recombinant marmoset P450 2B6 (Table 2).

Table 1. Sequence similarity of P450 cDNA and amino acids between marmosets and humans.

| Marmoset P450 | GenBank Access No. | Human P450 | Homology to Human P450 (%) | cDNA | Amino Acids |
|---------------|-------------------|------------|----------------------------|------|-------------|
| 1A1 [22]      | KJ922553          | 1A1        | 93                         | 90   |
| 1A2 [22]      | NM_001204434      | 1A2        | 93                         | 88   |
| 2A6 [39]      | KJ922555          | 2A6        | 93                         | 89   |
|               |                   | 2A7        | 91                         | 86   |
|               |                   | 2A13       | 94                         | 93   |
| 2B6 [30]      | KJ922556          | 2B6        | 91                         | 86   |
| 2C8 [12]      | NM_001204437      | 2C8        | 93                         | 88   |
| 2C18 [12]     | KJ922558          | 2C18       | 94                         | 93   |
| 2C19 [12]     | KJ922561          | 2C9        | 92                         | 86   |
|               |                   | 2C19       | 92                         | 86   |
| 2C58 [12]     | KJ922559          | 2C8        | 92                         | 87   |
|               |                   | 2C9        | 84                         | 79   |
|               |                   | 2C18       | 85                         | 78   |
|               |                   | 2C19       | 84                         | 78   |
| 2C76 [12]     | KJ922560          | 2C8        | 76                         | 68   |
|               |                   | 2C9        | 76                         | 68   |
|               |                   | 2C18       | 78                         | 70   |
|               |                   | 2C19       | 77                         | 69   |
| 2D6 [18]      | NM_001204438      | 2D6        | 92                         | 91   |
| 2D8 [18]      | KJ922562          | 2D6        | 89                         | 85   |
| 2E1 [26]      | NM_001267751      | 2E1        | 92                         | 89   |
| 2J2 [23]      | KX231948          | 2J2        | 94                         | 91   |
| 3A4 [24]      | NM_001204440      | 3A4        | 94                         | 90   |
| 3A5 [24]      | NM_001204442      | 3A5        | 93                         | 89   |
| 3A90 [24]     | NM_001204443      | 3A4        | 89                         | 82   |
|               |                   | 3A5        | 92                         | 88   |
|               |                   | 3A7        | 88                         | 78   |
|               |                   | 3A43       | 83                         | 74   |
| 4A11 [25]     | KX231949          | 4A11       | 92                         | 88   |
| 4F2 [19]      | KX231950          | 4F2        | 93                         | 93   |
| 4F3 [19]      | KX231951          | 4F3B       | 93                         | 93   |
| 4F7I[19]      | KX231952          | 4F11       | 91                         | 89   |
| 4F12 [19]     | KX231953          | 4F12       | 91                         | 87   |
Drug Oxidation Activities in Common Marmosets

Current Drug Metabolism, 2019, Vol. 20, No. 2

Fig. (1) contd....
Paclitaxel, tolbutamide, flurbiprofen, and diclofenac are typical human P450 2C9 and 2C19 substrates. Some species differences were seen in terms of the activities of hepatic microsomes between marmosets, cynomolgus monkeys, and humans with respect to paclitaxel 6α-hydroxylation, tolbutamide methyl hydroxylation, flurbiprofen 4′-hydroxylation, and diclofenac 4′-hydroxylation [12]. Compared with the activities in human livers, the paclitaxel 6α-hydroxylation and flurbiprofen 4′-hydroxylation activities were low in marmoset and cynomolgus monkey livers, respectively. This may be explained by the lower activities for these catalytic reactions in recombinant marmoset P450 2C19 and recombinant cynomolgus monkey P450 2C9 and 2C19 (Table 2). Although tolbutamide methyl hydroxylation was catalyzed by marmoset P450 2C8 and 2C19 with high activity levels (Table 2), the low tolbutamide methyl hydroxylation activity in marmoset livers compared with that in human livers may be accounted for by the lower capacity of marmoset P450 2C40 and the lower affinity of marmoset P450 2C8 compared to those of human P450 2C9 [12]. Marked diclofenac 5-hydroxylation activity was observed in marmoset liver [29]. Stereoselective oxidations of R- and S-omeprazole were mediated by hepatic microsomes from cynomolgus monkeys and common marmosets [21]. The roles of P450 2C19 and 3A4 enzymes for omeprazole 5-hydroxylation and sulfoxidation, respectively, were conserved between marmoset and human livers. However, there were conspicuous species differences in terms of the stereoselectivity of omeprazole 5-hydroxylation between human and marmoset livers: marmoset liver preferentially catalyzed S-omeprazole 5-hydroxylation, whereas human livers preferentially catalyzed R-omeprazole 5-hydroxylation. The stereoselectivity for omeprazole 5-hydroxylation between human and marmoset livers may be accounted for by the respective activities of recombinant marmoset P450 2C19 and human P450 2C9 (Table 2) [21].

Investigations of typical human P450 2D6 substrates showed that hepatic microsomes from humans, cynomolgus monkeys, and marmosets catalyzed regio- and stereoselective R- and S-metoprolol O-demethylation and bufuralol 1′-hydroxylation [27]. Recombinant human and marmoset P450 2D6 enzymes effectively catalyzed R-metoprolol O-demethylation, consistent with the activities of human and marmoset hepatic microsomes (Table 2). Investigations of typical human P450 2E1 substrates showed that hepatic microsomes from humans, cynomolgus monkeys, and marmosets catalyzed p-nitrophenol 2-hydroxylation, chlorzoxazone 6-hydroxylation, and theophylline 8-hydroxylation at similar rates [26]. Recombinant human, cynomolgus monkey, and marmoset P450 2E1 catalyzed these drug oxidation reactions, suggesting that P450 2E1 plays a similar role in drug-related oxidation reactions in human and marmoset livers (Table 2).

Analysis of typical human P450 3A probe substrates revealed that hepatic microsomes from marmosets catalyzed midazolam 1′- and 4-hydroxylation, nifedipine oxidation, testosterone 6β-hydroxylation, and progesterone 6β-hydroxylation in a similar manner to those from humans and cynomolgus monkeys [24, 29]. Moreover, recombinant marmoset P450 3A4, 3A5, and 3A90 also catalyzed these drug oxidation reactions in a similar manner to human P450 3A enzymes, which likely accounts for the similar
Table 2. Drug oxidation activities of recombinant marmoset, cynomolgus monkey, and human P450 enzymes expressed in *Escherichia coli.*

| Marker Reaction                  | Substrate Concentration (µM) | Marmoset P450 Activity, nmol product/min/nmol P450 | Cynomolgus Monkey P450 Activity, nmol product/min/nmol P450 | Human P450 Activity, nmol product/min/nmol P450 |
|---------------------------------|-----------------------------|---------------------------------------------------|-------------------------------------------------------------|---------------------------------------------|
| Ethoxyresorufin O-deethylation  | 2                           | 1A1<sup>a</sup> 39                                | 1A1<sup>a</sup> 4.5                                        | 1A1<sup>a</sup> 24                          |
|                                 | -                           | 1A2<sup>a</sup> 14                                | 1A2<sup>a</sup> 4.4                                        | 1A2<sup>a</sup> 4.4                          |
| 7-Ethoxycoumarin O-deethylation | 20                          | 2B6<sup>b</sup> 0.099                              | 2B6<sup>b</sup> 0.023                                      | 2B6<sup>b</sup> 0.036                        |
|                                 | 50                          | 2A6 2.6                                            | 2A23 9.0                                                  | 2A6 0.53                                    |
|                                 | -                           | -                                                  | 2A24 2.1                                                  | 2A13 34                                     |
|                                 | -                           | -                                                  | 2A26 4.7                                                  | -                                          |
|                                 | 100                         | 1A1<sup>a</sup> 54                                | 1A1<sup>a</sup> 11                                        | 1A1<sup>a</sup> 88                          |
|                                 | -                           | 1A2<sup>a</sup> 71                                | 1A2<sup>a</sup> 18                                        | 1A2<sup>a</sup> 8.3                         |
| Phenacetin O-deethylation       | 50                          | 2A6 3.4                                            | 2A23 1.7                                                  | 2A6 <0.1                                    |
|                                 | -                           | -                                                  | 2A24 <0.1                                                 | 2A13 6.0                                    |
|                                 | -                           | -                                                  | 2A26 <0.1                                                 | -                                          |
|                                 | 100                         | 1A1<sup>a</sup> 24                                | 1A1<sup>a</sup> 3.7                                       | 1A1<sup>a</sup> 8.2                         |
|                                 | -                           | 1A2<sup>a</sup> 26                                | 1A2<sup>a</sup> 5.7                                       | 1A2<sup>a</sup> 14                         |
| Coumarin 7-hydroxylation        | 100                         | 2A6 0.021                                          | 2A23 1.4                                                  | 2A6 5.8                                     |
|                                 | -                           | -                                                  | 2A24 0.4                                                  | 2A13 0.28                                   |
|                                 | -                           | -                                                  | 2A26 9.9                                                  | -                                          |
| Pentoxysorufin O-depentylation   | 20                          | 2B6<sup>b</sup> 0.025                              | 2B6<sup>b</sup> 0.014                                      | 2B6<sup>b</sup> 0.018                        |
| Propofol 4-hydroxylation        | 20                          | 2B6<sup>b</sup> 1.7                                | 2B6<sup>b</sup> 1.3                                       | 2B6<sup>b</sup> 4.1                         |
| Efavirenz 8-hydroxylation       | 20                          | 2B6<sup>b</sup> 0.35                               | 2B6<sup>b</sup> 0.014                                      | 2B6<sup>b</sup> <0.001                        |
| Paclitaxel 6α-hydroxylation     | 100                         | 2C8<sup>c</sup> 1.0                                | 2C8<sup>d</sup> 0.26                                       | 2C8 29                                      |
|                                 | -                           | 2C18<sup>c</sup> <0.5                              | 2C9<sup>d</sup> <0.001                                     | -                                          |
|                                 | -                           | 2C19<sup>c</sup> <0.5                              | 2C19<sup>d</sup> <0.001                                    | -                                          |
|                                 | -                           | 2C58<sup>c</sup> <0.5                              | 2C76<sup>d</sup> <0.001                                    | -                                          |
|                                 | -                           | 2C76<sup>c</sup> <0.5                              | 2C93<sup>d</sup> <0.001                                    | -                                          |
| Tolbutamide methyl hydroxylation| 2500                        | 2C8<sup>c</sup> 62                                 | 2C8 0.64                                                  | 2C8 1.1                                     |
|                                 | -                           | 2C18<sup>c</sup> 0.25                              | 2C9 0.85                                                  | 2C9 5.5                                     |
|                                 | -                           | 2C19<sup>c</sup> 19                                | 2C19 13                                                   | 2C19 0.37                                   |
|                                 | -                           | 2C58<sup>c</sup> 0.34                              | 2C76 1.5                                                  | -                                          |
|                                 | -                           | 2C76<sup>c</sup> 0.17                              | -                                                         | -                                          |

Table (2) contd....
| Marker Reaction                      | Substrate Concentration (µM) | Marmoset P450 Activity, nmol product/min/nmol P450 | Cynomolgus Monkey P450 Activity, nmol product/min/nmol P450 | Human P450 Activity, nmol product/min/nmol P450 |
|-------------------------------------|------------------------------|---------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------|
| Flurbiprofen 4-hydroxylation        | 100                          | 2C8<sup>c</sup> 0.54                             | 2C8<sup>d</sup> 0.01                                      | 2C9 21                                       |
|                                     | -                            | 2C18<sup>e</sup> <0.01                           | 2C9<sup>d</sup> 0.03                                      | -                                            |
|                                     | -                            | 2C19<sup>e</sup> 4.7                             | 2C19<sup>d</sup> 1.32                                     | -                                            |
|                                     | -                            | 2C58<sup>e</sup> 0.42                           | 2C76<sup>d</sup> 0.01                                     | -                                            |
|                                     | -                            | 2C76<sup>e</sup> <0.01                           | 2C93<sup>d</sup> 0.10                                     | -                                            |
| R-Warfarin 7-hydroxylation         | 100                          | 2C8<sup>c</sup> <0.0001                          | 2C8<sup>d</sup> 0.001                                     | 2C9 0.0028                                   |
|                                     | -                            | 2C18<sup>e</sup> 0.0028                          | 2C9<sup>d</sup> 0.0023                                    | -                                            |
|                                     | -                            | 2C19<sup>e</sup> 0.0053                          | 2C19<sup>d</sup> 5.0                                      | -                                            |
|                                     | -                            | 2C58<sup>e</sup> <0.0001                          | 2C76<sup>d</sup> 0.0024                                   | -                                            |
|                                     | -                            | 2C76<sup>e</sup> <0.0001                          | -                                                          | -                                            |
| S-Warfarin 7-hydroxylation         | 100                          | 2C8<sup>c</sup> <0.0001                          | 2C8<sup>d</sup> <0.00001                                  | 2C9 0.17                                     |
|                                     | -                            | 2C18<sup>e</sup> 0.0056                          | 2C9<sup>d</sup> 0.0029                                    | -                                            |
|                                     | -                            | 2C19<sup>e</sup> 0.17                            | 2C19<sup>d</sup> 0.21                                     | -                                            |
|                                     | -                            | 2C58<sup>e</sup> <0.0001                          | 2C76<sup>d</sup> 0.0012                                   | -                                            |
|                                     | -                            | 2C76<sup>e</sup> <0.0001                          | -                                                          | -                                            |
| R-Omeprazole 5-hydroxylation       | 100                          | 2C8<sup>f</sup> <0.4                            | 2C8<sup>d</sup> 1.5                                       | 2C8<sup>d</sup> <0.4                         |
|                                     | -                            | 2C18<sup>f</sup> 1.3                             | 2C9<sup>d</sup> 3.1                                       | 2C9<sup>d</sup> <0.4                         |
|                                     | -                            | 2C19<sup>f</sup> 9.9                             | 2C19<sup>d</sup> 27                                       | 2C19<sup>d</sup> 9.8                         |
|                                     | -                            | 2C58<sup>f</sup> 1.2                             | 2C76<sup>d</sup> 7.5                                      | -                                            |
|                                     | -                            | 2C76<sup>f</sup> <0.4                            | -                                                          | -                                            |
| S-Omeprazole 5-hydroxylation       | 100                          | 2C8<sup>f</sup> <0.4                            | 2C8<sup>d</sup> 1.7                                       | 2C8<sup>d</sup> <0.4                         |
|                                     | -                            | 2C18<sup>f</sup> 9.6                             | 2C9<sup>d</sup> 1.3                                       | 2C9<sup>d</sup> 1.1                         |
|                                     | -                            | 2C19<sup>f</sup> 17                              | 2C19<sup>d</sup> 28                                       | 2C19<sup>d</sup> 3.7                         |
|                                     | -                            | 2C58<sup>f</sup> 1.9                             | 2C76<sup>d</sup> 4.9                                      | -                                            |
|                                     | -                            | 2C76<sup>f</sup> <0.4                            | -                                                          | -                                            |
| Bufuralol 1'-hydroxylation         | 10                           | 2D6 2.7                                         | -                                                          | 2D6 5.6                                      |
|                                     | -                            | 2D8 1.6                                         | -                                                          | -                                            |
|                                     | 100                          | 2D6<sup>e</sup> 8.5                             | -                                                          | 2D6<sup>d</sup> 5.8                         |
|                                     | -                            | 2D8<sup>e</sup> 1.9                             | -                                                          | 3A4<sup>d</sup> 0.13                         |
|                                     | -                            | 3A4<sup>e</sup> 1.9                             | -                                                          | 3A5<sup>d</sup> 0.24                         |
|                                     | -                            | 3A5<sup>e</sup> 1.4                             | -                                                          | -                                            |
|                                     | -                            | 3A90<sup>e</sup> 0.81                           | -                                                          | -                                            |
|                                     | 200                          | 2D6 8.9                                         | -                                                          | -                                            |
|                                     | -                            | 2D44 4.9                                        | -                                                          | -                                            |
|                                     | -                            | 3A4 0.99                                        | -                                                          | -                                            |
|                                     | -                            | 3A5 2.4                                         | -                                                          | -                                            |
### Drug Oxidation Activities in Common Marmosets

#### Table: Drug Oxidation Activities

| Marker Reaction   | Substrate Concentration (µM) | P450 Activity, nmol product/min/ nmol P450 | Marmoset | Cynomolgus Monkey | Human |
|-------------------|------------------------------|------------------------------------------|----------|------------------|-------|
| **R-Metoprolol O-demethylation** | 10 | 2D6<sup>a</sup> 4.9 | - | - | 2D6<sup>a</sup> 18 |
|                   | - | 2D8<sup>b</sup> 0.12 | - | - | - |
| **S-Metoprolol O-demethylation** | 10 | 2D6<sup>b</sup> 3.5 | - | - | 2D6<sup>b</sup> 5.7 |
|                   | - | 2D8<sup>b</sup> 0.095 | - | - | - |
| Chlorzoxazone 6-hydroxylation | 50 | 2E1<sup>i</sup> 0.68 | 2E1<sup>i</sup> 0.76 | 2E1<sup>i</sup> 1.3 |
| p-Nitrophenol 2-hydroxylation | 50 | 2E1<sup>i</sup> 0.42 | 2E1<sup>i</sup> 0.63 | 2E1<sup>i</sup> 0.40 |
| Theophylline 8-hydroxylation | 500 | 2E1<sup>i</sup> 0.017 | 2E1<sup>i</sup> 0.015 | 2E1<sup>i</sup> 0.49 |
| Astemizole O-demethylation | 20 | 2J2<sup>j</sup> 0.32 | 2J2<sup>j</sup> 0.76 | 2J2<sup>j</sup> 1.69 |
| Midazolam 1'-hydroxylation | 10 | 3A4<sup>u</sup> 29 | 3A4<sup>u</sup> 18 | 3A4<sup>u</sup> 11 |
|                   | - | 3A5<sup>u</sup> 1.2 | 3A5<sup>u</sup> 36 | 3A5<sup>u</sup> 36 |
|                   | - | 3A90<sup>u</sup> 3.4 | - | - | - |
| Midazolam 4-hydroxylation | 10 | 3A4<sup>u</sup> 9.1 | 3A4<sup>u</sup> 15 | 3A4<sup>u</sup> 2.3 |
|                   | - | 3A5<sup>u</sup> 0.051 | 3A5<sup>u</sup> 2.7 | 3A5<sup>u</sup> 1.4 |
|                   | - | 3A90<sup>u</sup> 0.11 | - | - | - |
| Alprazolam 4-hydroxylation | 200 | 3A4<sup>u</sup> 1.4 | 3A4<sup>u</sup> 1.5 | 3A4<sup>u</sup> 0.74 |
|                   | - | 3A5<sup>u</sup> 0.022 | 3A5<sup>u</sup> 0.78 | 3A5<sup>u</sup> 0.46 |
|                   | - | 3A90<sup>u</sup> 0.054 | - | - | - |
| Nifedipine oxidation | 20 | 3A4<sup>u</sup> 25 | 3A4<sup>u</sup> 33 | 3A4<sup>u</sup> 22 |
|                   | - | 3A5<sup>u</sup> 1.1 | 3A5<sup>u</sup> 34 | 3A5<sup>u</sup> 7.8 |
|                   | - | 3A90<sup>u</sup> 2.8 | - | - | - |
| Testosterone 6β-hydroxylation | 50 | 3A4<sup>u</sup> 58 | 3A4<sup>u</sup> 50 | 3A4<sup>u</sup> 20 |
|                   | - | 3A5<sup>u</sup> 5.4 | 3A5<sup>u</sup> 60 | 3A5<sup>u</sup> 19 |
|                   | - | 3A90<sup>u</sup> 4.9 | - | - | - |
| Terfenadine t-butyl hydroxylation | 20 | 2J2<sup>i</sup> 0.47 | 2J2<sup>i</sup> 0.54 | 2J2<sup>i</sup> 0.95 |
| Ebastine 4-hydroxylation | 100 | 4F2<sup>a</sup> 0.013 | 4F2<sup>a</sup> <0.01 | 4F2<sup>a</sup> 0.081 |
|                   | - | 4F3<sup>a</sup> 0.026 | 4F3<sup>a</sup> 0.013 | 4F3B<sup>a</sup> 0.043 |
|                   | - | 4F71<sup>a</sup> 0.38 | 4F11<sup>a</sup> 0.94 | 4F11<sup>a</sup> 1.1 |
|                   | - | 4F12<sup>a</sup> 6.6 | 4F12<sup>a</sup> 2.8 | 4F12<sup>a</sup> 2.5 |

Data are taken from:<sup>a</sup> Uehara et al. [22];<sup>b</sup> Osbrio et al. [30];<sup>c</sup> Uehara et al. [12];<sup>d</sup> Uno et al. [40];<sup>e</sup> Hosoi et al. [41];<sup>f</sup> Uehara et al. [21];<sup>g</sup> Uehara et al. [24];<sup>h</sup> Uehara et al. [27];<sup>i</sup> Uehara et al. [26];<sup>j</sup> Uehara et al. [23]; and<sup>k</sup> Uehara et al. [19].
characteristics of P450 3A-dependent metabolism between human and marmoset livers (Table 2). Hydroxylations of terfenadine and ebastine were effectively mediated by hepatic microsomes from marmosets and cynomolgus monkeys [19, 25, 32]. Recombinant human, cynomolgus monkey, and marmoset P450 2J2 and 4F12 enzymes effectively catalyzed terfenadine and ebastine hydroxylation, respectively (Table 2).

The correlation coefficients among typical drug oxidation activities in hepatic microsomes from individual marmosets are summarized in Table 3. This kind of wide correlation analysis has not previously been carried out in the course of developing marmoset P450 studies. We previously reported that the activities of marmoset hepatic microsomes with respect to R-metoprolol O-demethylation, a probe reaction for P450 2D6/8, were correlated to those of P450 2D6/8-dependent bufuralol 1'-hydroxylation, as expected [27]. The R-metoprolol O-demethylation activities mediated by individual marmoset hepatic microsomes were also significantly correlated to those of midazolam 1'- and 4-hydroxylation, testosterone 6β-hydroxylation, and progesterone 6β-hydroxylation, probe reactions for marmoset P450 3A4/5/90 (Table 3) [27]. Interestingly, efavirenz 8-hydroxylation (a probe reaction for human P450 2B6) by marmoset hepatic microsomes was not significantly correlated with that mediated by marmoset P450 2B6 [30]. However, the activities for this reaction mediated by individual marmoset hepatic microsomes were correlated with those of marmoset P450 2C-dependent paclitaxel 6α-hydroxylation and R-omeprazole 5'-hydroxylation, and marmoset P450 3A-dependent nifedipine oxidation (Table 3), suggesting roles for marmoset P450 2C and 3A enzymes in efavirenz 8-hydroxylation.

3. DRUG OXIDATION ACTIVITIES MEDIATED BY MARMOSET INTESTINAL MICROSONES

Marmoset intestine also exhibits several drug oxidation activities [18, 19, 23, 24, 32]. The oxidation activities of pooled intestinal microsomes from humans, monkeys, and marmosets and microsomes from individual marmosets (n = 16) with respect to 10 substrates forming 11 metabolites are plotted in Fig. (2). Small-intestinal microsomes from marmosets catalyzed midazolam 1'- and 4-hydroxylation and nifedipine oxidation activities in roughly similar manners to those of humans and/or cynomolgus monkeys. Additionally, marmoset small-intestinal microsomes more efficiently catalyzed terfenadine r-buty1 hydroxylation than human small-intestinal microsomes did [32]. The activities of marmoset intestinal microsomes with respect to bufuralol 1'-hydroxylation (a probe reaction for P450 2D) and chloroxazone 6-hydroxylation (a probe reaction for P450 2E) were significantly correlated with those of midazolam 1'- and 4-hydroxylations, probe reactions for marmoset P450 3A4/5/90 (Table 4). Moreover, marmoset P450 3A4/90 and 4F12 in small intestine played important roles in terfenadine r-buty1 hydroxylation [32], suggesting that marmosets could be a human model for the first-pass extraction of terfenadine and related substrates.

4. OVERVIEW AND FUTURE ASPECTS

There are important similarities and differences among drug oxidations by human, monkey, and marmoset hepatic microsomes, as mentioned above. Additional differences also became evident during our extensive studies [34-41]. For example, caffeine is a typical P450 substrate differently metabolized among these primates, i.e., caffeine is N-3-demethylated by human livers, N-7-demethylated (to form theophylline) by monkey livers, and 8-hydroxylated by marmoset livers [34]. We also found that marmoset pulmonary P450 2F1 oxidized biphenyl and 7-ethoxyoumarin [31], and kidney P450 4A11 is a ω-hydroxylase with respect to arachidonic acid and lauric acid [25]. Furthermore, data for marmosets regarding other important drug-metabolizing enzymes and transporters (e.g., flavin-containing monoxygenases [35], aldehyde

Table 3. Correlation coefficients for drug oxidation activities of hepatic microsomes from individual marmosets.

|                  | Pro- | Efavi-renz | Pacli-taxel | Tolbu-tamid | Flur-bipro-fen | Diclofen-a (4') | Diclofen-a (5) | S-War-farin | R-Ome-prazole | R-Metoprol | Theoph-ylcline | Mida-zolam (1') | Mida-zolam (4) | Nifedip-ine | Testos-terone | Proges-terone |
|------------------|-----|------------|------------|------------|---------------|----------------|----------------|-------------|---------------|------------|---------------|----------------|---------------|-------------|--------------|--------------|
| Efavirenz        | 0.05|            |            |            |               |                |                |             |               |            |               |                |               |             |              |              |
| Paclitaxel       | 0.19| 0.75**     |            |            |               |                |                |             |               |            |               |                |               |             |              |              |
| Tolbutamide      | 0.17| 0.70*      | 0.72*      |            |               |                |                |             |               |            |               |                |               |             |              |              |
| Flurbiprofen     | 0.64*| 0.22     | 0.29        | 0.43       |               |                |                |             |               |            |               |                |               |             |              |              |
| Diclofenac (5)   | 0.07| 0.60*      | 0.67*      | 0.54       | 0.18          | 0.42           |                |             |               |            |               |                |               |             |              |              |
| S-Warfarin       | 0.22| 0.48      | 0.48         | 0.77**     | 0.41          | 0.72*          | 0.35           |             |               |            |               |                |               |             |              |              |
| R-Omeprazole     | 0.31| 0.71*      | 0.85**     | 0.82**     | 0.54*         | 0.51           | 0.47           | 0.81**      |               |            |               |                |               |             |              |              |
| R-Metoprol       | 0.04| 0.71*      | 0.76**     | 0.83**     | 0.06          | 0.68*          | 0.66*          | 0.72*       | 0.75**       |            |               |                |               |             |              |              |
| Theophylline     | 0.05| 0.71*      | 0.71*      | 0.63       | 0.32          | 0.76**         | 0.72*          | 0.62*       | 0.69*        | 0.81**     |               |                |               |             |              |              |
| Midazolam (1')   | 0.44| 0.55*      | 0.80**     | 0.63       | 0.72*         | 0.11           | 0.48           | 0.42        | 0.79**       | 0.81**     | 0.58*         |                |               |             |              |              |
| Midazolam (4)    | 0.19| 0.74*      | 0.94**     | 0.57       | 0.37          | 0.33           | 0.64*          | 0.43        | 0.83**       | 0.66*      | 0.75**        | 0.86**         |               |             |              |              |
| Nifedipine       | -0.15| 0.90**    | 0.91**     | 0.72*      | 0.07          | 0.54           | 0.69*          | 0.39        | 0.72*        | 0.78**     | 0.68*         | 0.53           | 0.83**        |             |              |              |
| Testosterone     | 0.35| 0.67*      | 0.89**     | 0.66       | 0.53*         | 0.17           | 0.61*          | 0.41        | 0.81**       | 0.56*      | 0.63*         | 0.96**         | 0.95**        | 0.74*       |              |              |
| Progesterone     | 0.27| 0.73*      | 0.91**     | 0.64       | 0.45          | 0.22           | 0.70*          | 0.41        | 0.79**       | 0.64*      | 0.67*         | 0.90*          | 0.95**        | 0.77**      | 0.98**       |              |
| Terfenadine      | -0.12| 0.62*     | 0.45       | 0.01       | 0.11          | 0.78**         | 0.48           | 0.65*       | 0.59*        | 0.75**     | 0.75**        | 0.11           | 0.41          | 0.72*       | 0.19         | 0.28        |

*P<0.05; **P<0.01.
Drug oxidation activities in common marmosets, Current Drug Metabolism, 2019, Vol. 20, No. 2

Oxidases [36], catechol-O-methyltransferase [37], and ABC transporters [38]) are now available. Investigations of marmoset UDP-glucuronosyltransferases, glutathione S-transferases, and carboxy esterases are ongoing projects to help elucidate drug metabolism and disposition in marmosets as a model animal.

**CONCLUSION**

Taken together, the current surveys of the inter-individual variability of marmoset P450-dependant drug oxidation activities in hepatic and intestinal microsomes should help to further...
our understanding of apparent species differences in drug metabolism and disposition in humans and nonhuman primates. Moreover, the information summarized here will help inform the extrapolation to humans of preclinical data obtained using common marmosets.

CONSENT FOR PUBLICATION
Not applicable.

CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS
We thank Makiko Shimizu, Norie Murayama, Yusuke Kamiya, Yuya Haghira, Takako Suzuki, Mirai Kawano, Sakura Ishii, Eriko Okamoto, and Yukako Yuki for their support with the experiments, and David Smallbones for editing a draft of this manuscript. This work was partly supported by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research 17K15520 (S.U.) and 17K08425 (H.Y.) and in part by “Construction of System for Spread of Primate Model Animals” under the Strategic Research Program for Brain Sciences of Japan Agency for Medical Research and Development.

REFERENCES
[1] Nelson, D.R.; Zeldin, D.C.; Hoffman, S.M.G.; Maltsi, L.J.; Wain, H.M.; Neber, D.W. Comparison of cytochrome P450(CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenomics, 2004, 4, 1-18.
[2] Guengerich, F. P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol., 2008, 21(1), 70-83.
[3] Sato, K.; Iiwa, R.; Kumita, W.; Henry, R.; Sakuma, T.; Ito, R.; Nozu, R.; Inoue, T.; Katano, I.; Sasaki, E.; Okahara, N.; Okahara, J.; Shimizu, Y.; Yamamoto, M.; Hanazawa, K.; Kawakami, T.; Kametani, Y.; Suzuki, R.; Takahashi, T.; Weinstein, E. J.; Yamamoto, T.; Sakakibara, Y.; Habu, S.; Hata, J.; Okano, H.; Sasaki, E.; Generation of a Nonhuman Primate Model of Severe Combined Immunodeficiency Using Highly Efficient Genome Editing. Cell Stem Cell, 2016, 19(1), 127-138.
[4] Kurata, Y.; Makinodan, F.; Shimamura, N.; Katoh, M. Metabolism of di(2-ethylhexyl) phthalate(DEHP): Comparative study in common marmoset(Callithrix jacchus) juveniles and fetal marmosets and rats. J. Toxicol. Sci., 2012, 37(1), 33-49.
[5] Shimizu, M.; Ivanov, S.; Uno, Y.; Uehara, S.; Inoue, T.; Murayama, N.; Onodera, J.; Sasaki, E.; Yamazaki, H. Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression in common marmoset(Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. PLoS One, 2014, 9(6), e100936.
[6] Uehara, S.; Uno, Y.; Inoue, T.; Murayama, N.; Shinimizu, M.; Sasaki, E.; Yamazaki, H. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Drug Metab. Dispos., 2015, 43, 735-742.
[7] Uno, Y.; Iwasaki, K.; Yamazaki, H.; Nelson, D. R. Macaque cytochromes P450: Nomenclature, transcript, gene, genomic structure, and function. Drug Metab. Rev., 2011, 43, 346-361.
[8] Uno, Y.; Uehara, S.; Yamazaki, H. Utility of non-human primates and human drug-metabolizing cytochrome P450 enzymes. Biochem. Pharmacol., 2016, 121, 1-7.
[9] Uehara, S.; Inoue, T.; Uoto, M.; Toda, A.; Shimizu, M.; Uno, Y.; Sasaki, E.; Yamazaki, H. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol, and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica, 2016, 46, 163-168.
[10] Uoto, M.; Suezumi, H.; Mitsu, M.; Kawano, M.; Toda, A.; Uehara, S.; Uno, Y.; Shimizu, M.; Sasaki, E.; Yamazaki, H. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica, 2016, 46, 1049-1055.
[11] Obach, R. S.; Lombardo, F.; Waters, N. J. Trend analysis of a database of intravenous CYP enzymes in humans for 670 drug compounds. Drug Metab. Dispos., 2008, 36(7), 1385-1405.
[12] Uehara, S.; Uno, Y.; Inoue, S.; Kawano, M.; Shimizu, M.; Toda, A.; Uoto, M.; Sasaki, E.; Yamazaki, H. Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug Metab. Dispos., 2015, 43, 1408-1416.
[13] Uehara, S.; Uno, Y.; Inoue, T.; Kawano, M.; Shimizu, M.; Toda, A.; Uoto, M.; Sasaki, E.; Yamazaki, H. Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug Metab. Dispos., 2016, 44, 911-915.
[14] Kusama, T.; Toda, A.; Shimizu, M.; Uehara, S.; Inoue, T.; Uno, Y.; Uoto, M.; Sasaki, E.; Yamazaki, H. Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R- and S-warfarin using individual marmoset physiologically based pharmacokinetic models. Xenobiotica, 2018, 48(10), 1072-1077.
[15] Toda, A.; Uehara, S.; Inoue, T.; Uoto, M.; Kusama, T.; Shimizu, M.; Uno, Y.; Mogi, M.; Sasaki, E.; Yamazaki, H. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 450 probes caffeine, warfarin, omeprazole, metoprolol, and midazolam in common marmosets genotyped for cytochrome P450 2C19. Xenobiotica, 2018, 48, 720-726.
[16] Uehara, S.; Uno, Y.; Suzuki, T.; Inoue, T.; Uoto, M.; Sasaki, E.; Yamazaki, H. Strong induction of cytochrome P450 1A3A, but not P450 2B, in cultured hepatocytes from common marmosets and nonhuman primates. Xenobiotica, 2016, 46, 1799-1808.
[17] Uehara, S.; Uno, Y.; Haghira, Y.; Murayama, N.; Shinimizu, M.; Inoue, T.; Sasaki, E.; Yamazaki, H. Metabolism of 3-

112 Current Drug Metabolism, 2019, Vol. 20, No. 2 Uehara et al.
[26] Uehara, S.; Uno, Y.; Tomioka, E.; Inoue, T.; Sasaki, E.; Yamazaki, H. Functional characterization and tissue expression of marmoset cytochrome P450 2E1. *Biopharm. Drug Dispos.*, **2017**, *38*, 394-397.

[27] Uehara, S.; Ishii, S.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Regio- and stereo-selective oxidation of a cardiovascular drug metoprolol mediated by cytochrome P450 2D and 3A enzymes in marmoset livers. *Drug Metab. Dispos.*, **2017**, *45*, 896-899.

[28] Nakanishi, K.; Uehara, S.; Kusama, T.; Inoue, T.; Shimura, K.; Kamiya, Y.; Murayama, N.; Shimizu, M.; Uno, Y.; Sasaki, E.; Yamazaki, H. *In vivo and in vitro* diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. *Biochem. Pharmacol.*, **2018**, *152*, 272-278.

[29] Nakanishi, K.; Uehara, S.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Progesterone hydroxylation by cytochromes P450 2C and 3A enzymes in marmoset liver microsomes. *Xenobiotica*, **2018**, *48*, 757-763.

[30] Oshio, T.; Uehara, S.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver. *Xenobiotica*, **2019**, *49*(3), 265-269.

[31] Uehara, S.; Uno, Y.; Oshio, T.; Inoue, T.; Sasaki, E.; Yamazaki, H. Marmoset pulmonary cytochrome P450 2F1 oxidizes diphenyl and 7-ethoxycoumarin and hepatic human P450 substrates. *Xenobiotica*, **2018**, *48*, 656-662.

[32] Uehara, S.; Yuki, Y.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines. *Xenobiotica*, **2018**, *48*, 342-347.

[33] Uehara, S.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Correction to "Molecular cloning, tissue distribution, and functional characterization of marmoset cytochrome P450 1A1, 1A2, and 1B1". *Drug Metab. Dispos.*, **2017**, *45*, 956.

[34] Utoh, M.; Murayama, N.; Uno, Y.; Onose, Y.; Hosaka, S.; Fujino, H.; Shimizu, M.; Iwasaki, K.; Yamazaki, H. Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. *Xenobiotica*, **2013**, *43*, 1037-1042.

[35] Uehara, S.; Shimizu, M.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Marmoset flavin-containing monoxygenase 3 in liver is a major benzydamine and sulindac sulfide oxygenase. *Drug Metab. Dispos.*, **2017**, *45*, 497-500.

[36] Uehara, S.; Uno, Y.; Okamoto, E.; Inoue, T.; Sasaki, E.; Yamazaki, H. Molecular cloning and characterization of marmoset aldehyde oxidase. *Drug Metab. Dispos.*, **2017**, *45*, 883-886.

[37] Uehara, S.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Cloning and expression of a novel catechol-O-methyltransferase in common marmosets. *J. Vet. Med. Sci.*, **2017**, *79*, 267-272.

[38] Uehara, S.; Uno, Y.; Inoue, T.; Sasaki, E.; Yamazaki, H. Molecular cloning and tissue distribution of a novel marmoset ABC transporter. *Biopharm. Drug Dispos.*, **2018**, *39*, 59-63.

[39] Uehara, S.; Murayama, N.; Yamazaki, H.; Uno, Y. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. *Xenobiotica*, **2010**, *40*, 621-629.

[40] Uno, Y.; Uehara, S.; Kohara, S.; Iwasaki, K.; Nagata, R.; Fukuzaki, K.; Utoh, M.; Murayama, N.; Yamazaki, H. Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey. *PLoS One*, **2011**, *6*, e16923.

[41] Hosoi, Y.; Uno, Y.; Murayama, N.; Fujino, H.; Shukuya, M.; Iwasaki, K.; Shimizu, M.; Utoh, M.; Yamazaki, H. Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. *Biochem. Pharmacol.*, **2012**, *84*, 1691-1695.